In addition, multivariate Cox regression analysis suggested that ANXA2 was an independent risk factor for the clinical prognosis of glioma patients, which further indicated that ANXA2 was a negative marker for the prognosis of glioma and could be used for the molecular biological diagnosis and evaluation of glioma. Here, ANXA2 is linked to central nervous system cancer.